Researchers at The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas Medical Branch at Galveston (UTMB Health) have discovered a potential new antibody therapy for COVID-19. The study was published in Nature Communications.
The annual symposium of the CPRIT Therapeutic Antibody Core took place on Friday, December 11, 2020, from 1:00 pm Central Time. For the safety of participants during the COVID-19 pandemic, the symposium was held online via WebEx. Speakers highlighted the core’s capacities and provided examples of successful core collaborations.
The annual symposium of the CPRIT Therapeutic Antibody Core took place on Tuesday, December 10, 2019, at the University of Texas Health Science Center at Houston (UTHealth – Houston). Speakers highlighted the core’s capacities and provided examples of successful core collaborations.
On January 10, 2020, Dr. Zhiqiang An was inducted into the University of Kentucky College of Agriculture, Food and Environment Hall of Distinguished Alumni. The award, honoring Dr. An’s contributions as a leader in the field of antibody engineering for cancer therapies, is the highest alumni award the college bestows.
At the end of November 2019, the Council of the American Association for the Advancement of Science (AAAS) Fellows announced Dr. Zhiqiang An, along with other members of AAAS, had earned lifetime distinction of AAAS Fellow this year. The honor recognizes diverse accomplishments in contributions to science and technology. AAAS Fellows include astronomer Maria Mitchell, inventor Thomas Edison, anthropologist Margaret Mead, computer scientist Grace Hopper, and popular science author Jared Diamond, and 2019 Nobel laureates James Peebles and John B. Goodenough.
Results of a Therapeutic Antibody Core collaborative project with Dr. Philipp Scherer were published in a Cell Metabolism article.